We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Simple DNA Test Could Identify the Risk of Inherited Diseases

By LabMedica International staff writers
Posted on 04 Mar 2010
An inexpensive, fast, and accurate test using a drop of saliva pinpoints variations at critical points along the DNA chain. More...


Researchers from the University of Edinburgh (UK) developed the new method, which is based on dynamic chemical analysis, and delivers reliable results without the need for the expensive enzymes used in conventional DNA testing. The new method allows the analysis of single-nucleotide polymorphism, indel, and abasic sites using mass spectrometry as a readout tool. Differences or omissions in the DNA code could then show if someone is healthy, susceptible to disease, or is suffering from a serious medical condition.

Currently, the test can look for genetic variations for only one disease at a time, but the researchers hope the technique could be used eventually to decode the whole human genome, which would give information about genetic variations across the whole spectrum of disease. The test takes about 30 minutes, and the methodology is suitable for the dual analysis of heterozygous samples. The study describing the new technique was published in the February 2010 issue of the journal Angewandte Chemie.

"What we have developed is a way of testing chemically; that means not using enzymes, which are the current method,” said lead author Juan Diaz-Mochon, Ph.D., of the school of chemistry. "The technology offers a speedy, cost-efficient alternative to existing methods of DNA analysis.”

"The test could help spot diseases, such as pancreatic cancer, early. It could also indicate if someone had a risk of other diseases, such as heart problems or dementia,” added coauthor Prof. Mark Bradley, Ph.D. "We plan to test the technology further, extend our collaborations with leading researchers and companies in the DNA sequencing field, and establish our first commercial operations within the next six months.”

Related Links:

University of Edinburgh



New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Hematology Consumables
Bioblood Devices
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.